The inhibitory role of recombinant P‑selectin glycoprotein ligand immunoglobulin G on portal vein thrombosis based on a novel rat model

Wei,Yunhai; Shao,Jie; Shen,Hua; Wang,Yan; Cao,Guoliang; Chen,Wenxian; Zhang,Jinyu; Yin,Lei

doi:10.3892/etm.2019.7394

The inhibitory role of recombinant P‑selectin glycoprotein ligand immunoglobulin G on portal vein thrombosis based on a novel rat model

Authors:
- Yunhai Wei
- Jie Shao
- Hua Shen
- Yan Wang
- Guoliang Cao
- Wenxian Chen
- Jinyu Zhang
- Lei Yin
View Affiliations

Affiliations: Surgical Department, Huzhou Central Hospital, Zhejiang University Huzhou Hospital, Huzhou, Zhejiang 313000, P.R. China, Integrated Traditional Chinese and Western Medicine Surgery, Huzhou Maternal and Child Health Care Hospital, Huzhou, Zhejiang 313000, P.R. China, Ultrasonography Department, Huzhou Central Hospital, Zhejiang University Huzhou Hospital, Huzhou, Zhejiang 313000, P.R. China, Department of Gastrointestinal Surgery, Huzhou Central Hospital, Zhejiang University Huzhou Hospital, Huzhou, Zhejiang 313000, P.R. China
Published online on: March 13, 2019 https://doi.org/10.3892/etm.2019.7394
Pages: 3589-3597
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study aimed to reveal a novel method for constructing a portal vein thrombosis (PVT) model in rats and to evaluate the inhibitory role of recombinant P‑selectin glycoprotein ligand immunoglobulin G (rPSGL‑Ig) on the formation of PVT. The PVT model was constructed in rats through intermittent portal vein obstruction (IPVO) combined with endangium destruction. A total of 4 mg/kg rPSGL‑Ig was intraperitoneally pre‑injected into rats 1 h prior to model construction. Changes in the thrombus size and vessel diameter were observed by B‑scan ultrasonography. Histopathological changes in the portal vein, central hepatic vein and vasa intestini tenuis were observed using hematoxylin and eosin staining. Additionally, histopathological changes in the portal vein were observed by transmission electron microscopy. A total of 8 mg/kg rPSGL‑Ig or 2x104 U/kg urokinase were used to compare the thrombolytic effects and thrombus sizes. The PVT model was successfully constructed in rats, and exhibited a significantly greater thrombus size and vessel diameter compared with the control group (P<0.05). Intervention with rPSGL‑Ig significantly inhibited the formation of PVT, and resulted in a significantly lower thrombus size and vessel diameter compared with the model group (P<0.05). Additionally, histopathological changes in the portal vein, central hepatic vein and vasa intestini tenuis in PVT rats were considerably reversed following the intervention with rPSGL‑Ig. rPSGL‑Ig demonstrated a lower thrombolytic effect compared with that of URO. IPVO combined with endangium destruction effectively constructed a PVT model in rats. rPSGL‑Ig effectively prevented PVT in rats. rPSGL‑Ig may be used in future studies for the treatment of patients with PVT.

View Figures

View References

1	Cohen R, Mallet T, Gale M, Soltys R and Loarte P: Portal vein thrombosis. Case Rep Vasc Med. 2015:8230632015.PubMed/NCBI
2	Winslow ER, Brunt LM, Drebin JA, Soper NJ and Klingensmith ME: Portal vein thrombosis after splenectomy. Am J Surg. 184:631–636. 2002. View Article : Google Scholar : PubMed/NCBI
3	Manzano-Robleda Mdel C, Barranco-Fragoso B, Uribe M and Méndez-Sánchez N: Portal vein thrombosis: What is new? Ann Hepatol. 14:20–27. 2015.PubMed/NCBI
4	Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, Grandone E and Balzano A: Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 40:736–741. 2004. View Article : Google Scholar : PubMed/NCBI
5	Lixue D, Wujun W, Zhang Y, Sun Z, Haitian H and Liu Q: Clinical analysis of portal vein thrombosis after splenocaval shunt plus devascularization in treatment of portal hypertension. Chin J Hepatobiliary Surg. 16:353–355. 2010.(In Chinese).
6	Harmanci O and Bayraktar Y: Portal hypertension due to portal venous thrombosis: Etiology, clinical outcomes. World J Gastroenterol. 13:2535–2540. 2007. View Article : Google Scholar : PubMed/NCBI
7	Geng JG, Chen M and Chou KC: P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. Curr Med Chem. 11:2153–2160. 2004. View Article : Google Scholar : PubMed/NCBI
8	André P, Hartwell D, Hrachovinovã I, Saffaripour S and Wagner DD: Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA. 97:13835–13840. 2000. View Article : Google Scholar : PubMed/NCBI
9	Myers DD Jr, Schaub R, Wrobleski SK, Londy FJ III, Fex BA, Chapman AM, Greenfield LJ and Wakefield TW: P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb Haemost. 85:423–429. 2001. View Article : Google Scholar : PubMed/NCBI
10	Myers D, Wrobleski S, Londy F, Fex B, Hawley A, Schaub R, Greenfield L and Wakefield T: New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig. Thromb Haemost. 87:374–382. 2002. View Article : Google Scholar : PubMed/NCBI
11	Eppihimer MJ and Schaub RG: P-Selectin-dependent inhibition of thrombosis during venous stasis. Arterioscler Thromb Vasc Biol. 20:2483–2488. 2000. View Article : Google Scholar : PubMed/NCBI
12	Théorêt JF, Bienvenu JG, Kumar A and Merhi Y: P-selectin antagonism with recombinant p-selectin glycoprotein ligand-1 (rPSGL-Ig) inhibits circulating activated platelet binding to neutrophils induced by damaged arterial surfaces. J Pharmacol Exp Ther. 298:658–664. 2001.PubMed/NCBI
13	Reyers I, Mussoni L, Donati MB and de Gaetano G: Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res. 18:669–674. 1980. View Article : Google Scholar : PubMed/NCBI
14	Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Köllnberger M, Wakefield TW, Lämmle B, Massberg S and Wagner DD: von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 117:1400–1407. 2011. View Article : Google Scholar : PubMed/NCBI
15	Nakase H, Heimann A and Kempski O: Alterations of regional cerebral blood flow and oxygen saturation in a rat sinus-vein thrombosis model. Stroke. 27:720–728. 1996. View Article : Google Scholar : PubMed/NCBI
16	Seyed Mortaz SS, Golfam F, Khalaj AR, Taheri HR and Kholdi N: The effect of distal vein branch ligation in side-to-side arterivenous fistula on the patency rate and complication in one year. Daneshvar Medicine. 16:19–24. 2009.
17	Xu Z, Lioi J, Mu J, Kamocka MM, Liu X, Chen DZ, Rosen ED and Alber M: A multiscale model of venous thrombus formation with surface-mediated control of blood coagulation cascade. Biophys J. 98:1723–1732. 2010. View Article : Google Scholar : PubMed/NCBI
18	Khalid A, Azeez EA, Bhatti TH and Eshak Y: Transcutanous electric nerve stimulation and deep venous thrombosis. Anesthesia & Analgesia. 86:S121998. View Article : Google Scholar
19	Nosaka M, Ishida Y, Kimura A and Kondo T: Time-dependent appearance of intrathrombus neutrophils and macrophages in a stasis-induced deep vein thrombosis model and its application to thrombus age determination. Int J Legal Med. 123:235–240. 2009. View Article : Google Scholar : PubMed/NCBI
20	Fei Y, Zong GQ, Chen J and Liu RM: Evaluation of the value of d-dimer, P-selectin, and platelet count for prediction of portal vein thrombosis after devascularization. Clin Appl Thromb Hemost. 22:471–475. 2016. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Bing Y, Zhao QH and Yu Z: Effect of urokinase on vein wall remodeling after deep vein thrombosis in rats. Di San Jun Yi Da Xue Xue Bao. 32:1970–1975. 2010.(In Chinese).
23	Kyogashima M, Onaya J, Hara A and Taketomi T: Sulfatide can markedly enhance thrombogenesis in rat deep vein thrombosis model. Glycoconj J. 15:915–922. 1998. View Article : Google Scholar : PubMed/NCBI
24	Nosaka M, Ishida Y, Kimura A and Kondo T: Immunohistochemical detection of MMP-2 and MMP-9 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation. Int J Legal Med. 124:439–444. 2010. View Article : Google Scholar : PubMed/NCBI
25	Burcharth F: Percutaneous transhepatic catheterization of the portal venous system. Springer. (Japan). 1991. View Article : Google Scholar
26	Furie B and Furie BC: Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med. 10:171–178. 2004. View Article : Google Scholar : PubMed/NCBI
27	Bedard PW, Clerin V, Sushkova N, Tchernychev B, Antrilli T, Resmini C, Keith JC Jr, Hennan JK, Kaila N, Debernardo S, et al: Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther. 324:497–506. 2008. View Article : Google Scholar : PubMed/NCBI
28	Miszti-Blasius K, Debreceni IB, Felszeghy S, Dezso B and Kappelmayer J: Lack of P-selectin glycoprotein ligand-1 protects mice from thrombosis after collagen/epinephrine challenge. Thromb Res. 127:228–234. 2011. View Article : Google Scholar : PubMed/NCBI
29	Myers DD Jr, Henke PK, Wrobleski SK, Hawley AE, Farris DM, Chapman AM, Knipp BS, Thanaporn P, Schaub RG, Greenfield LJ and Wakefield TW: P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model. J Vasc Surg. 36:928–938. 2002. View Article : Google Scholar : PubMed/NCBI
30	McEver RP: P-selectin and PSGL-1: Exploiting connections between inflammation and venous thrombosis. Thromb Haemost. 87:364–365. 2002. View Article : Google Scholar : PubMed/NCBI
31	Kneuer C, Ehrhardt C, Radomski MW and Bakowsky U: Selectins-potential pharmacological targets? Drug Discov Today. 11:1034–1040. 2006. View Article : Google Scholar : PubMed/NCBI
32	Marder VJ and Sherry S: Thrombolytic therapy: Current status. N Engl J Med. 318:1512–1520. 1988. View Article : Google Scholar : PubMed/NCBI